Skip to content

Contact +44 (0) 20 7060 7474 email us

Company Information

GlaxoSmithKline: PharmaVitae Profile

PharmaVitae Profile

Publication Date January 2007
Publisher Datamonitor
Product Type Report
Pages 170
ISBN Number not applicable
Product Code DAT00601

Price

£1,980.00
approximately: $2,998 | €2,210

pdf

Buy Now

print £2,015 ($3,051 | €2,249)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark GSK's performance against key rivals in the ethical pharmaceutical sector
  • Understand quantitatively how the relative balance of growth from launches and declines from expiries will leave GSK's revenues treadmilling 200511
  • Evaluate the prospects of the company's Centres of Excellence in Drug Discovery R&D structure boosting long-term growth

Contents

  • Chapter 1 Executive Summary
    • Key findings
    • Historical and forecast ethical sales performance
    • Therapeutic strategy
    • Launch and expiry outlook
    • Externalization, geographic and molecule type strategies
    • Externalization strategy
    • Geographic strategy
    • Molecule type strategy
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 2 Corporate History
    • Key findings
    • Background
    • M&A history
    • Wellcome
    • Glaxo
    • Glaxo Wellcome
    • Beecham
    • Smith Kline
    • SmithKline Beecham
    • Key historical drug launches by component GSK companies
    • M&A strategy
    • R&D overview
    • Current corporate structure
  • Chapter 3 Historical Performance
    • Key findings
    • Introduction
    • Revenue and growth rate analysis, 2002-05
    • Revenue and growth rate vs. peer set
    • Product analysis, 2002-05
    • Key growth drivers
    • Growth resistors
    • Operating revenue and cost analysis, 2002-05
    • Operating revenue/cost analysis
  • Chapter 4 Forecast Performance
    • Key findings
    • Introduction
    • Revenue and growth rate, 2005-11
    • Product analysis, 2005-11
    • Growth drivers
    • Therapy area analysis, 2005-11
    • Urology
    • Oncology
    • Diabetes & endocrinology
    • CNS
    • Infectious disease
    • Respiratory
    • Therapy area focus
    • Launches and expiries analysis, 2005-11
    • Launch portfolio
    • Core portfolio
    • Expiry portfolio
    • Launch/core/expiry configuration
    • Externalization analysis, 2005-11
    • Geographic analysis, 2005-11
    • Molecule type analysis, 2005-11
  • Chapter 5 Key Products And Competitors
    • Key findings
    • Overview
    • Seretide/Advair
    • Super Advair
    • Allermist
    • Flixonase/Flonase
    • Avandia/Avandamet
    • Wellbutrin
    • Imigran/Imitrex
    • Trexima
    • Lamictal
    • Cervarix
    • Tykerb
    • Zofran
    • Avodart
    • R&D pipeline
  • Chapter 6 Appendix
    • IMS vs. company-reported data reconciliation
    • Abbreviations
    • Exchange rates
  • Table Of Tables
    • Table 1: Peer set overview
    • Table 2: Operating revenue/cost analysis ($m), 2002-05
    • Table 3: Operating cost ratio analysis (% of total revenues), 2002-05
    • Table 4: Product portfolio overview, sales ($m), 2005-11
    • Table 5: Therapy area overview, sales ($m), 2005-11
    • Table 6: Launch portfolio overview, sales ($m), 2005-11
    • Table 7: Core portfolio overview, sales ($m), 2005-11
    • Table 8: Expiry portfolio overview, sales ($m), 2005-11
    • Table 9: Externally developed portfolio, 2005-11 ($m)
    • Table 10: Molecule type overview, sales ($m), 2005-11
    • Table 11: Key products overview
    • Table 12: Seretide/Advair: overview
    • Table 13: Seretide/Advair: sales forecast ($m), 2005-11
    • Table 14: Seretide/Advair: newsflow
    • Table 15: Super Advair: overview
    • Table 16: Super Advair: sales forecast ($m), 2005-11
    • Table 17: Super Advair: newsflow
    • Table 18: Allermist: overview
    • Table 19: Allermist: sales forecast ($m), 2005-11
    • Table 20: Allermist: newsflow
    • Table 21: Flixonase/Flonase: overview
    • Table 22: Flixonase/Flonase: sales forecast ($m), 2005-11
    • Table 23: Flixonase: newsflow
    • Table 24: Avandia: overview
    • Table 25: Avandamet: overview
    • Table 26: Avandia: sales forecast ($m), 2005-11
    • Table 27: Avandamet: sales forecast ($m), 2005-11
    • Table 28: Avandia/Avandamet: newsflow
    • Table 29: Wellbutrin Franchise: overview
    • Table 30: Wellbutrin Franchise: sales forecast ($m), 2005-11
    • Table 31: Wellbutrin Franchise: newsflow
    • Table 32: Imigran/Imitrex: overview
    • Table 33: Imigran/Imitrex: sales forecast ($m), 2005-11
    • Table 34: Imigran/Imitrex: newsflow
    • Table 35: Trexima: overview
    • Table 36: Trexima: sales forecast ($m), 2005-11
    • Table 37: Trexima: newsflow
    • Table 38: Lamictal: overview
    • Table 39: Lamictal: sales forecast ($m), 2005-11
    • Table 40: Lamictal: newsflow
    • Table 41: Cervarix: overview
    • Table 42: Cervarix: sales forecast ($m), 2005-11
    • Table 43: Cervarix: newsflow
    • Table 44: Tykerb: overview
    • Table 45: Tykerb: sales forecast ($m), 2005-11
    • Table 46: Tykerb: newsflow
    • Table 47: Zofran: overview
    • Table 48: Zofran: sales forecast ($m), 2005-11
    • Table 49: Zofran: newsflow
    • Table 50: Avodart: overview
    • Table 51: Avodart: sales forecast ($m), 2005-11
    • Table 52: Avodart: newsflow
    • Table 53: Novartis' R&D pipeline (Phase I-registration)
    • Table 54: Exchange rates, 2005
  • Table Of Figures
    • Figure 1: Historical and forecast ethical sales performance (% CAGR), Roche and Big Pharma peer set
    • Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2005
    • Figure 3: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), GSK
    • Figure 4: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), peer set
    • Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2005
    • Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2011
    • Figure 7: SWOT analysis of GSK
    • Figure 8: M&A/divestment history
    • Figure 9: Revenue & growth rate (ethical sales) ($m), 2002-05
    • Figure 10: Ethical revenue ($m) and growth rate (%) vs. peer set, 2002-05
    • Figure 11: Growth drivers/resistor products of historical revenue performance ($m), 2002-05
    • Figure 12: Operating revenue/cost analysis ($m), 2002-05
    • Figure 13: Operating cost ratio analysis (% of total revenues), 2002-05
    • Figure 14: Operating cost ratio vs. peer set, 2002-05
    • Figure 15: Ethical revenue ($m) and growth rate (%), 2005-11
    • Figure 16: Top five products by sales ($m), 2005
    • Figure 17: Top five products by sales ($m), 2005
    • Figure 18: Growth drivers and resistors by product, 2005-11
    • Figure 19: Key strategic products, sales ($m), 2005-11
    • Figure 20: Ethical sales by therapy area ($m), 2005-11
    • Figure 21: Growth drivers and resistors by therapy area (%), 2005-11
    • Figure 22: Ethical sales by therapy area (%), 2005-11
    • Figure 23: Therapy area focus compared with peer set (% total ethical sales), 2005
    • Figure 24: Therapy area focus compared with peer set (% total ethical sales), 2011
    • Figure 25: Launch schedule, sales ($m), 2005-11
    • Figure 26: Core products sales growth ($m), 2005-11
    • Figure 27: Expiry schedule, sales ($m), 2005-11
    • Figure 28: Launch, core and expiry, sales ($m), 2005-11
    • Figure 29: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), GSK
    • Figure 30: Launch, core and expiry, absolute sales growth, 2005-11 (sales as % of 2005 sales), peer set
    • Figure 31: Externalization dependency, sales ($m), 2005-11
    • Figure 32: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2005-11
    • Figure 33: Externalization dependency vs. peer set, % total sales, 2005
    • Figure 34: Externalization dependency vs. peer set, % total sales, 2011
    • Figure 35: Geographical sales breakdown ($m), 2005-11
    • Figure 36: Growth drivers and resistors by geography, sales ($m), 2005-11
    • Figure 37: US dependency vs. peer set, % total sales, 2005
    • Figure 38: US dependency vs. peer set, % total sales, 2011
    • Figure 39: Growth drivers and resistors by molecule type, sales ($m), 2005-11
    • Figure 40: Molecule type sales breakdown ($m), 2005-11
    • Figure 41: Biologics dependency vs. peer set, % total sales, 2005
    • Figure 42: Biologics dependency vs. peer set, % total sales, 2011
    • Figure 43: IMS vs. company-reported ethical sales discrepancy ($m), 2005
    • Figure 44: IMS vs. company-reported ethical sales forecast growth rates (%), 2005-11